On Wednesday, S&P Global received a positive adjustment to its Relative Strength (RS) Rating, from 67 to 75.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's unique RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves. See if S&P Global can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
While the stock is not near an ideal buying range right now, see if it manages to form and break out of a proper base.
While the company's top line growth fell last quarter from 42% to 37%, EPS grew -4%, up from -7% in the previous report. Keep an eye out for the company's next round of numbers on or around Feb. 9.
S&P Global earns the No. 3 rank among its peers in the Commercial Services-Market Research industry group. Thomson Reuters and S&P Global are also among the group's highest-rated stocks.
